



#### Editor-in-Chief

Pedro T Ramirez (USA)

#### Associate Editors

Antonio Gonzalez (Spain)  
Anna Fagotti (Italy)  
Michael Frumovitz (USA)  
Rene Pareja (Colombia)  
Anuja Jhingran (USA)

#### Video Editor

Luis Chiva (Spain)

#### Social Media Editor

Ane Gerda Zahl Eriksson (Norway)

#### Managing Editor

Lindsey Struckmeyer (USA)

#### Editorial Office

*International Journal of Gynecological Cancer*, BMJ Journals  
Two Hudson Square, 3rd Floor,  
Hoboken, NJ 07030 USA  
E: [ijgc@jeditorial.com](mailto:ijgc@jeditorial.com)

#### Production Editor

Michaela Joseph  
E: [production.ijgc@bmj.com](mailto:production.ijgc@bmj.com)

#### Customer support

For general queries and support with  
existing and new subscriptions:  
W: [support.bmj.com](mailto:support.bmj.com)  
T: +44 (0)20 7111 1105  
E: [support@bmj.com](mailto:support@bmj.com)

#### Self-archiving and permissions

W: [bmj.com/company/productservices/rights-and-licensing/](http://bmj.com/company/productservices/rights-and-licensing/)  
E: [bmj.permissions@bmj.com](mailto:bmj.permissions@bmj.com)

**Disclaimer:** The Editor of *International Journal of Gynecological Cancer* has been granted editorial freedom and *International Journal of Gynecological Cancer* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *International Journal of Gynecological Cancer* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *International Journal of Gynecological Cancer* does not imply endorsement. Neither *International Gynecologic Cancer Society* and *European Society of Gynaecological Oncology* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *International Journal of Gynecological Cancer* (except for liability which cannot be legally excluded).

**Copyright:** © 2020 IGCS and ESGO. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without prior permission.

The *International Journal of Gynecological Cancer (IJGC)* is published by BMJ Publishing Group Ltd and typeset by Exeter Premedia Services Private Limited, Chennai, India.

### Editorials

**281** Encouraging worldwide adoption of sentinel lymph node biopsies for gynecologic malignancies

*M Frumovitz, A Buda*

**283** Sentinel lymph node mapping in endometrial cancer – areas where further research is needed

*A Obermair, N R Abu-Rustum*

### Lead article

**285** Does small volume metastatic lymph node disease affect long-term prognosis in early cervical cancer?



*A Nica, L T Gien, S E Ferguson, A Covens*

### Original research

**291** Retrospective detection of isolated tumor cells by immunohistochemistry in sentinel lymph node biopsy performed for endometrial carcinoma: is there clinical significance?

*E A Goebel, J D St Laurent, M R Nucci, C M Feltmate*

**299** Sentinel lymph node biopsy in early stage endometrial cancer: a Turkish gynecologic oncology group study (TRSGO-SLN-001)

*S Taşkın, D Altın, D Vatanserver, N Tokgozoglu, E Karabük, H Turan, Ö Takmaz, I Kahramanoglu, M M Naki, M Güngör, F Köse, F Ortac, M Arvas, A Ayhan, C Taskiran*

**305** Robotic sentinel lymph node (SLN) mapping in endometrial cancer: SLN symmetry and implications of mapping failure

*A J Stephens, J A Kennard, C K Fitzsimmons, M Manyam, J E Kendrick, C Singh, N D McKenzie, S Ahmad, R W Holloway*

**311** Technetium-99m-indocyanine green versus technetium-99m-methylene blue for sentinel lymph node biopsy in early-stage endometrial cancer

*S Cabrera, V Bebia, S Franco-Camps, C Forcada, D Villasboas-Rosciolesi, I Navales, A Pérez-Benavente, A Gil-Moreno*

**318** Comparison of outcomes between the one-step and two-step sentinel lymph node mapping techniques in endometrial cancer

*Y-N Kim, K J Eoh, J-Y Lee, E J Nam, S Kim, Y-T Kim, S W Kim*

**325** Cervical versus endometrial injection for sentinel lymph node detection in endometrial cancer: a randomized clinical trial

*Ş Gezer, S Duman Öztürk, T Hekimsoy, Ç Vural, S İşgören, İ Yücesoy, A Çorakçı*

**332** Sentinel lymph node mapping in endometrial cancer: performance of hysteroscopic injection of tracers

*F Martinelli, A Ditto, G Bogani, U Leone Roberti Maggiore, M Signorelli, V Chiappa, F Raspagliosi*

**339** Pelvic sentinel lymph node biopsy in endometrial cancer—a simplified algorithm based on histology and lymphatic anatomy

*M Bollino, B Geppert, C Lönnfors, H Falconer, S Salehi, J Persson*

**346** Defining the learning curve for successful staging with sentinel lymph node biopsy for endometrial cancer among surgeons at an academic institution

*K Tucker, S-A Staley, P A Gehrig, J T Soper, J F Boggess, A Ivanova, E Rossi*

**352** Implementation of a sentinel lymph node mapping algorithm for endometrial cancer: surgical outcomes and hospital charges

*K I Stewart, J S Eska, R F Harrison, R Suidan, A Abraham, G B Chisholm, L A Meyer, S N Westin, N D Fleming, M Frumovitz, T A Aloia, P T Soliman*

**358** Frozen section examination of sentinel lymph nodes can be used as a decisional tool in the surgical management of early cervical cancer

*A Rychlik, M A Angeles, F Migliorelli, S Croce, E Mery, A Martinez, G Ferron, F Guyon, D Querleu*

**364** Role of one-step nucleic acid amplification (OSNA) to detect sentinel lymph node low-volume metastasis in early-stage cervical cancer

*N Bizzarri, L Pedone Anchora, G F Zannoni, A Santoro, M Valente, F Inzani, V Gallotta, C Conte, V Chiantera, F Fanfani, A Fagotti, G Ferrandina, G Scambia*

- 372** Standard ultra-staging compared to one-step nucleic acid amplification for the detection of sentinel lymph node metastasis in endometrial cancer patients: a retrospective cohort comparison  
*F Fanfani, G Monterossi, M L Di Meo, E La Fera, F Dell'Orto, A Gioè, M Lamanna, D Ferrari, E De Ponti, P Perego, S Restaino, R Carlo, G F Zannoni, F Landoni, G Scambia, A Buda*

- 378** Combining positron emission tomography/computed tomography, radiomics, and sentinel lymph node mapping for nodal staging of endometrial cancer patients  
*C Crivellaro, C Landoni, F Elisei, A Buda, M Bonacina, T Grassi, L Monaco, D Giuliani, I Gotuzzo, S Magni, G Di Martino, M Delle Marchette, L Guerra, F Landoni, R Fruscio, C Messa, E De Bernardi*

- 383** Evolution and outcomes of sentinel lymph node mapping in vulvar cancer  
*V Broach, N R Abu-Rustum, Y Sonoda, C L Brown, E Jewell, G Gardner, D S Chi, O Zivanovic, M M Leitao Jr*

---

## Review

- 387** Current and novel mapping substances in gynecologic cancer care  
*L A Moukarzel, J Feinberg, E J Levy, M M Leitao, Jr.*

- 394** Pathology of sentinel lymph nodes: historical perspective and current applications in gynecologic cancer  
*E Euscher*

---

## Clinical trial

- 402** Can we extend the indication for sentinel node biopsy in vulvar cancer? A nationwide feasibility study from Sweden  
*D Zach, P Kannisto, K Stenström Bohlin, L Moberg, P Kjölhede*

---

## Corners of the world

- 406** Sentinel lymph node detection in patients with cervical cancer in a public hospital in Guatemala  
*E E Estrada*

---

## Video article

- 407** Sentinel lymph node mapping for uterine cancer: a practical illustration of injection and mapping techniques using robot-assisted fluorescence imaging  
*J J Mueller, M M Leitao*